PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC

Explore clinical trials studying PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC. Study availability and eligibility vary by location and protocol.

1 public trial 0 recruiting studies

Refine in advanced search Browse all conditions

PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC trial results

Active, Not Recruiting

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

NCT06635824

Conditions: Lung Diseases, Lung Neoplasms, Neoplasms, +5 more
Locations: Arizona Blood and Cancer Specialists Tucson, Arizona, United States

Usc Norris Comprehensive Cancer Center Los Angeles, California, United States

Kaiser Permanente Vallejo Medical Center Vallejo, California, United States

Ocala Oncology Center P.L. Ocala, Florida, United States

View all 247 locations

View Trial Details

PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC

PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC trial results

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

Related conditions